Prescient Therapeutics Limited


ASX-listed clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) is focused on the development of revolutionary personalised therapies for challenging cancers having unmet medical need. Prescient’s key programs are universal CAR-T and targeted therapies. Both approaches seek to improve patient outcomes and develop new tools for clinicians to combat cancer.

Notably, Prescient Therapeutics is backed by a leading team of global cancer specialists who hold extensive experience in advancing new cancer therapies.

Prescient has a comprehensive product pipeline of personalised cancer treatments for several different cancers:

Source: PTX Website

CAR-T therapies include OmniCAR and Cell Therapy Enhancement Programs

OmniCAR program: Prescient’s universal CAR-T platform, OmniCAR, employs technology that is licensed from the University of Pennsylvania and Oxford University.

PTX’s pioneering OmniCAR program will allow unprecedented control and flexibility over the current generation CAR-T methods.

Interestingly, Prescient has announced three next-generation OmniCAR programs for AML, Her2+ solid tumours and glioblastoma multiforme (GBM). PTX has also entered into a new research agreement with Peter MacCallum Cancer Centre to advance its CAR-T programs.

Cell Therapy Enhancements (CTE): Prescient’s CTE programs are progressing well with initial promising findings. Two CTE programs are underway with Peter MacCallum and Carina Biotech, respectively.

Targeted Therapies - PTX-100 and PTX-200  

PTX-100 is a first in class RhoA inhibitor and can block GGT-1 (geranylgeranyl transferase-1), a crucial cancer growth enzyme.

  • Currently, the compound is in a PK/PD basket study to treat hematological and solid cancers, focusing on malignancies with Ras and RhoA mutations.
  • In an earlier Phase 1 trial for advanced solid tumours, PTX-100 achieved stable disease and was well tolerated.

PTX-200, a novel PH domain inhibitor, blocks Akt pathway. Akt plays a vital role in the development of numerous malignancies, including breast and ovarian cancer and leukemia.  

  • PTX-200 has a unique mechanism of particularly inhibiting the Akt pathway in a comparatively safe manner, unlike other drugs targeting Akt inhibition.
  • PTX-200 has previously reported promising data in Phase 2a study for HER2-negative breast cancer and Phase 1b trial in ovarian cancer (recurrent or persistent platinum-resistant).
  • Currently, Prescient is assessing PTX-200 in relapsed and refractory Acute Myeloid Leukemia.

Contact Information

company address Level 4, 100 Albert Road, SOUTH MELBOURNE, VIC, AUSTRALIA, 3205

company phone(03) 9692 7222

company email[email protected]

company website

Similar Companies

Load More
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK